|
|
|
|
T-cell lymphomas (TCLs) are aggressive, diverse cancers, making up 10–15% of non-Hodgkin lymphomas. Current therapies offer limited success, with high relapse rates and poor survival, leaving most patients with few options and underscoring the need for novel treatments.
|
|
|
|
|
To make immune cell therapies more accessible, the biopharmaceutical industry is focused on developing innovative manufacturing processes, reducing production time, and optimizing supply chain management in order to lower costs without compromising product quality or safety.
|
|
|
|
|
CAR-T therapies are transforming cancer treatment. Researchers are now improving their effectiveness and safety, while also exploring their use outside hematological malignancies, such as for solid tumors and other cell types, enabling a broader range of applications.
|
|
|
|
|
|
|
